# Massimiliano Mazzone

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 143 papers | 12,944 citations | 52 h-index | 113 g-index |
| 156 ext. papers | 15,448 ext. citations | 15.4 avg, IF | 6.19 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 143 | The c-MET receptor tyrosine kinase contributes to neutrophil-driven pathology in cutaneous leishmaniasis.. *PLoS Pathogens*, **2022**, 18, e1010247 | 7.6 | |
| 142 | Repression of hypoxia-inducible factor-1 contributes to increased mitochondrial reactive oxygen species production in diabetes.. *ELife*, **2022**, 11, | 8.9 | 5 |
| 141 | Iron supplementation is sufficient to rescue skeletal muscle mass and function in cancer cachexia.. *EMBO Reports*, **2022**, e53746 | 6.5 | 2 |
| 140 | IL1 Promotes Immune Suppression in the Tumor Microenvironment Independent of the Inflammasome and Gasdermin D. *Cancer Immunology Research*, **2021**, 9, 309-323 | 12.5 | 10 |
| 139 | PlexinA4 mediates cytotoxic T cell trafficking and exclusion in cancer. *Cancer Immunology Research*, **2021**, | 12.5 | 1 |
| 138 | BNIP3 promotes HIF-1 driven melanoma growth by curbing intracellular iron homeostasis. *EMBO Journal*, **2021**, 40, e106214 | 13 | 8 |
| 137 | Hypoxia-induced miR-210 modulates the inflammatory response and fibrosis upon acute ischemia. *Cell Death and Disease*, **2021**, 12, 435 | 9.8 | 1 |
| 136 | How metabolism bridles cytotoxic CD8 T cells through epigenetic modifications. *Trends in Immunology*, **2021**, 42, 401-417 | 14.4 | 6 |
| 135 | Macrophage miR-210 induction and metabolic reprogramming in response to pathogen interaction boost life-threatening inflammation. *Science Advances*, **2021**, 7, | 14.3 | 7 |
| 134 | Protein Phosphatase 2A Mediates YAP Activation in Endothelial Cells Upon VEGF Stimulation and Matrix Stiffness. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 675562 | 5.7 | 4 |
| 133 | Tumor vessel co-option probed by single-cell analysis. *Cell Reports*, **2021**, 35, 109253 | 10.6 | 8 |
| 132 | Isolation and separation of murine tumor-associated macrophages (TAMs) subpopulations from orthotopic 4T1 breast tumors. *STAR Protocols*, **2021**, 2, 100481 | 1.4 | |
| 131 | ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3. *Cancer Letters*, **2021**, 510, 13-23 | 9.9 | 1 |
| 130 | N-acetylaspartate release by glutaminolytic ovarian cancer cells sustains protumoral macrophages. *EMBO Reports*, **2021**, 22, e51981 | 6.5 | 2 |
| 129 | Metabolic traits ruling the specificity of the immune response in different cancer types. *Current Opinion in Biotechnology*, **2021**, 68, 124-143 | 11.4 | 1 |
| 128 | Neutrophils Fuel Effective Immune Responses through Gluconeogenesis and Glycogenesis. *Cell Metabolism*, **2021**, 33, 411-423.e4 | 24.6 | 25 |
| 127 | MicroRNA-Mediated Metabolic Shaping of the Tumor Microenvironment. *Cancers*, **2021**, 13, | 6.6 | 7 |

| | | | |
|---|---|---|---|
| 126 | Differential Effects of Trp53 Alterations in Murine Colorectal Cancer. *Cancers*, **2021**, 13, | 6.6 | 1 |
| 125 | Leptin brain entry via a tanycytic LepR-EGFR shuttle controls lipid metabolism and pancreas function. *Nature Metabolism*, **2021**, 3, 1071-1090 | 14.6 | 16 |
| 124 | Betulinic Acid Hydroxamate is Neuroprotective and Induces Protein Phosphatase 2A-Dependent HIF-1 Stabilization and Post-transcriptional Dephosphorylation of Prolyl Hydrolase 2. *Neurotherapeutics*, **2021**, 18, 1849-1861 | 6.4 | 2 |
| 123 | Understanding Metal Dynamics Between Cancer Cells and Macrophages: Competition or Synergism?. *Frontiers in Oncology*, **2020**, 10, 646 | 5.3 | 7 |
| 122 | B55 PP2A Limits Endothelial Cell Apoptosis During Vascular Remodeling: A Complementary Approach To Disrupt Pathological Vessels?. *Circulation Research*, **2020**, 127, 707-723 | 15.7 | 10 |
| 121 | Neutrophilic HGF-MET signaling exacerbates intestinal inflammation. *Journal of Crohn's and Colitis*, **2020**, | 1.5 | 5 |
| 120 | Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. *Cancer Immunology, Immunotherapy*, **2020**, 69, 1673-1697 | 7.4 | 19 |
| 119 | An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates. *Cancer Cell*, **2020**, 37, 21-36.e13 | 24.3 | 93 |
| 118 | Impact of Immunometabolism on Cancer Metastasis: A Focus on T Cells and Macrophages. *Cold Spring Harbor Perspectives in Medicine*, **2020**, 10, | 5.4 | 3 |
| 117 | Glufosinate constrains synchronous and metachronous metastasis by promoting anti-tumor macrophages. *EMBO Molecular Medicine*, **2020**, 12, e11210 | 12 | 8 |
| 116 | Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development. *Cancers*, **2020**, 12, | 6.6 | 11 |
| 115 | DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance. *Genome Biology*, **2020**, 21, 182 | 18.3 | 13 |
| 114 | Macrophage-derived glutamine boosts satellite cells and muscle regeneration. *Nature*, **2020**, 587, 626-631 | 50.4 | 39 |
| 113 | Immunity, Hypoxia, and Metabolism-the Ménage Trois of Cancer: Implications for Immunotherapy. *Physiological Reviews*, **2020**, 100, 1-102 | 47.9 | 84 |
| 112 | Podoplanin-Expressing Macrophages Promote Lymphangiogenesis and Lymphoinvasion in Breast Cancer. *Cell Metabolism*, **2019**, 30, 917-936.e10 | 24.6 | 67 |
| 111 | Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. *Science Signaling*, **2019**, 12, | 8.8 | 45 |
| 110 | Activation of the VEGFC/VEGFR3 Pathway Induces Tumor Immune Escape in Colorectal Cancer. *Cancer Research*, **2019**, 79, 4196-4210 | 10.1 | 34 |
| 109 | Tumor-associated macrophages: a short compendium. *Cellular and Molecular Life Sciences*, **2019**, 76, 1447-1458 | 7.1 | 47 |

| | | | |
|---|---|---|---|
| 108 | Role and therapeutic potential of dietary ketone bodies in lymph vessel growth. *Nature Metabolism* , **2019**, 1, 666-675 | 14.6 | 24 |
| 107 | Reprogramming of Amino Acid Transporters to Support Aspartate and Glutamate Dependency Sustains Endocrine Resistance in Breast Cancer. *Cell Reports*, **2019**, 28, 104-118.e8 | 10.6 | 40 |
| 106 | Blood Vessel Proximity Shapes Cancer Cell Metabolism. *Cell Metabolism*, **2019**, 30, 16-18 | 24.6 | 5 |
| 105 | Caspase-8 modulates physiological and pathological angiogenesis during retina development. *Journal of Clinical Investigation*, **2019**, 129, 5092-5107 | 15.9 | 9 |
| 104 | Hypoxia Inducible Factor Activation Prevents Renal Mitochondria Dysfunction and Improves Cortical Oxygenation in Type 1 Diabetic Mice. *FASEB Journal*, **2019**, 33, lb591 | 0.9 | |
| 103 | Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells. *Cancer Research*, **2019**, 79, 1938-1951 | 10.1 | 33 |
| 102 | Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. *Annual Review of Physiology*, **2019**, 81, 535-560 | 23.1 | 24 |
| 101 | Metabolism and TAM functions-it takes two to tango. *FEBS Journal*, **2018**, 285, 700-716 | 5.7 | 43 |
| 100 | Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?. *JAMA Oncology*, **2018**, 4, 131-132 | 13.4 | 1 |
| 99 | Neutrophils enhance early Trypanosoma brucei infection onset. *Scientific Reports*, **2018**, 8, 11203 | 4.9 | 15 |
| 98 | Quiescent Endothelial Cells Upregulate Fatty Acid β-Oxidation for Vasculoprotection via Redox Homeostasis. *Cell Metabolism*, **2018**, 28, 881-894.e13 | 24.6 | 99 |
| 97 | Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation. *Cell Metabolism*, **2018**, 28, 866-880.e15 | 24.6 | 83 |
| 96 | The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. *Seminars in Cancer Biology*, **2018**, 52, 107-116 | 12.7 | 46 |
| 95 | Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. *Nature Communications*, **2018**, 9, 4112 | 17.4 | 36 |
| 94 | SLC25A26 overexpression impairs cell function via mtDNA hypermethylation and rewiring of methyl metabolism. *FEBS Journal*, **2017**, 284, 967-984 | 5.7 | 27 |
| 93 | The mTOR and PP2A Pathways Regulate PHD2 Phosphorylation to Fine-Tune HIF1α Levels and Colorectal Cancer Cell Survival under Hypoxia. *Cell Reports*, **2017**, 18, 1699-1712 | 10.6 | 60 |
| 92 | Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. *Nature Communications*, **2017**, 8, 14206 | 17.4 | 50 |
| 91 | Hypoxia determines survival outcomes of bacterial infection through HIF-1alpha dependent re-programming of leukocyte metabolism. *Science Immunology*, **2017**, 2, | 28 | 45 |

| | | | |
|---|---|---|---|
| 90 | PHD2 Targeting Overcomes Breast Cancer Cell Death upon Glucose Starvation in a PP2A/B55-Mediated Manner. *Cell Reports*, **2017**, 18, 2836-2844 | 10.6 | 18 |
| 89 | MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability. *Molecular Cancer*, **2017**, 16, 55 | 42.1 | 10 |
| 88 | Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. *Immunity*, **2017**, 47, 789-802.e9 | 32.3 | 142 |
| 87 | Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth. *EMBO Molecular Medicine*, **2017**, 9, 1629-1645 | 12 | 40 |
| 86 | Retinoid X receptor suppresses a metastasis-promoting transcriptional program in myeloid cells via a ligand-insensitive mechanism. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 10725-10730 | 11.5 | 17 |
| 85 | -ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. *Nature Immunology*, **2017**, 18, 985-994 | 19.1 | 394 |
| 84 | Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. *Cell Reports*, **2017**, 20, 1654-1666 | 10.6 | 153 |
| 83 | Loss of Caveolin-1 in Metastasis-Associated Macrophages Drives Lung Metastatic Growth through Increased Angiogenesis. *Cell Reports*, **2017**, 21, 2842-2854 | 10.6 | 36 |
| 82 | Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. *EMBO Journal*, **2017**, 36, 2373-2389 | 13 | 103 |
| 81 | Blockade of Glutamine Synthetase Enhances Inflammatory Response in Microglial Cells. *Antioxidants and Redox Signaling*, **2017**, 26, 351-363 | 8.4 | 42 |
| 80 | Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. *Oncotarget*, **2017**, 8, 93688-93703 | 3.3 | 1 |
| 79 | Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses. *Journal of Clinical Investigation*, **2017**, 127, 3407-3420 | 15.9 | 48 |
| 78 | Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer. *Gut*, **2016**, 65, 990-1000 | 19.2 | 49 |
| 77 | Tumour hypoxia causes DNA hypermethylation by reducing TET activity. *Nature*, **2016**, 537, 63-68 | 50.4 | 354 |
| 76 | FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. *Scientific Reports*, **2016**, 6, 33453 | 4.9 | 131 |
| 75 | Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis. *Cell Metabolism*, **2016**, 24, 701-715 | 24.6 | 234 |
| 74 | Vessel Normalization in the Spot-LIGHT of Cancer Treatment. *Trends in Molecular Medicine*, **2016**, 22, 85-87 | 11.5 | 3 |
| 73 | The impact of hypoxia on tumor-associated macrophages. *Journal of Clinical Investigation*, **2016**, 126, 3672-3679 | 15.9 | 250 |

| | | | |
|---|---|---|---|
| 72 | MIF-Mediated Hemodilution Promotes Pathogenic Anemia in Experimental African Trypanosomosis. *PLoS Pathogens*, **2016**, 12, e1005862 | 7.6 | 16 |
| 71 | The tumour microenvironment harbours ontogenically distinct dendritic cell populations with opposing effects on tumour immunity. *Nature Communications*, **2016**, 7, 13720 | 17.4 | 145 |
| 70 | Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. *European Heart Journal*, **2016**, 37, 2993-2997 | 9.5 | 33 |
| 69 | The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts. *Cell Reports*, **2015**, 12, 992-1005 | 10.6 | 54 |
| 68 | Factor-inhibiting HIF-1 (FIH-1) is required for human vascular endothelial cell survival. *FASEB Journal*, **2015**, 29, 2814-27 | 0.9 | 21 |
| 67 | Identification of a chronic non-neurodegenerative microglia activation state in a mouse model of peroxisomal □-oxidation deficiency. *Glia*, **2015**, 63, 1606-20 | 9 | 34 |
| 66 | Functional MMP-10 is required for efficient tissue repair after experimental hind limb ischemia. *FASEB Journal*, **2015**, 29, 960-72 | 0.9 | 14 |
| 65 | PHD1 regulates p53-mediated colorectal cancer chemoresistance. *EMBO Molecular Medicine*, **2015**, 7, 1350-65 | 12 | 35 |
| 64 | Phospholipase C gamma 1 (PLCG1) R707Q mutation is counterselected under targeted therapy in a patient with hepatic angiosarcoma. *Oncotarget*, **2015**, 6, 36418-25 | 3.3 | 19 |
| 63 | Semaphorin7A regulates neuroglial plasticity in the adult hypothalamic median eminence. *Nature Communications*, **2015**, 6, 6385 | 17.4 | 83 |
| 62 | MET is required for the recruitment of anti-tumoural neutrophils. *Nature*, **2015**, 522, 349-53 | 50.4 | 245 |
| 61 | Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation. *Oncotarget*, **2015**, 6, 11295-309 | 3.3 | 27 |
| 60 | Sixty shades of oxygen-an attractive opportunity for cancer immunotherapy. *Annals of Translational Medicine*, **2015**, 3, 187 | 3.2 | 2 |
| 59 | Oxygen Signaling in Physiological and Pathological Angiogenesis **2015**, 329-349 | | |
| 58 | Prolyl hydroxylase domain 1 (PHD1) to mediate chemoresistance in colorectal cancer.. *Journal of Clinical Oncology*, **2015**, 33, e14534-e14534 | 2.2 | |
| 57 | Immune response triggered by a novel molecular crosstalk of major hallmarks of cancer: Angiogenesis, mismatch repair, and immune pathways.. *Journal of Clinical Oncology*, **2015**, 33, 11054-11054 | 2.2 | 1 |
| 56 | Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population. *Cancer Research*, **2014**, 74, 24-30 | 10.1 | 290 |
| 55 | The anti-proliferative effect of L-carnosine correlates with a decreased expression of hypoxia inducible factor 1 alpha in human colon cancer cells. *PLoS ONE*, **2014**, 9, e96755 | 3.7 | 43 |

| | | | |
|---|---|---|---|
| 54 | Brain endothelial cells control fertility through ovarian-steroid-dependent release of semaphorin 3A. *PLoS Biology*, **2014**, 12, e1001808 | 9.7 | 42 |
| 53 | The Fragile X Protein binds mRNA s involved in cancer progression and modulates metastasis formation. *EMBO Molecular Medicine*, **2014**, 6, 567-568 | 12 | 78 |
| 52 | Altering the intratumoral localization of macrophages to inhibit cancer progression. *OncoImmunology*, **2014**, 3, e27872 | 7.2 | 8 |
| 51 | Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization. *Journal of Clinical Investigation*, **2014**, 124, 4335-50 | 15.9 | 39 |
| 50 | Histidine-rich glycoprotein uptake and turnover is mediated by mononuclear phagocytes. *PLoS ONE* , **2014**, 9, e107483 | 3.7 | 14 |
| 49 | Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. *Oncotarget*, **2014**, 5, 12978-89 | 3.3 | 27 |
| 48 | Endothelial Cell Reactions to Oxygen: Implications for Cancer **2014**, 267-282 | | |
| 47 | Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. *Cancer Cell*, **2013**, 24, 695-709 | 24.3 | 373 |
| 46 | Tanycytic VEGF-A boosts blood-hypothalamus barrier plasticity and access of metabolic signals to the arcuate nucleus in response to fasting. *Cell Metabolism*, **2013**, 17, 607-17 | 24.6 | 224 |
| 45 | Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. *Cancer Cell*, **2013**, 23, 477-88 | 24.3 | 110 |
| 44 | Renal CD133(+)/CD73(+) progenitors produce erythropoietin under hypoxia and prolyl hydroxylase inhibition. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 1234-41 | 12.7 | 17 |
| 43 | The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. *EMBO Molecular Medicine*, **2013**, 5, 1523-36 | 12 | 78 |
| 42 | PHD2 regulates arteriogenic macrophages through TIE2 signalling. *EMBO Molecular Medicine*, **2013**, 5, 843-57 | 12 | 35 |
| 41 | The "cord of life" serving antiangiogenic therapy. *Blood*, **2013**, 121, 4254-5 | 2.2 | |
| 40 | Overcoming resistance to antiangiogenic therapies. *Oncologist*, **2012**, 17, 1039-50 | 5.7 | 47 |
| 39 | Genetic deficiency in plasma protein HRG enhances tumor growth and metastasis by exacerbating immune escape and vessel abnormalization. *Cancer Research*, **2012**, 72, 1953-63 | 10.1 | 27 |
| 38 | VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. *Lancet Oncology, The*, **2012**, 13, 724-33 | 21.7 | 154 |
| 37 | Loss of the oxygen sensor PHD3 enhances the innate immune response to abdominal sepsis. *Journal of Immunology*, **2012**, 189, 1955-65 | 5.3 | 61 |

| | | | |
|---|---|---|---|
| 36 | miR-511-3p modulates genetic programs of tumor-associated macrophages. *Cell Reports*, **2012**, 1, 141-54 | 10.6 | 162 |
| 35 | Gene-targeting of Phd2 improves tumor response to chemotherapy and prevents side-toxicity. *Cancer Cell*, **2012**, 22, 263-77 | 24.3 | 101 |
| 34 | Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform. *EMBO Molecular Medicine*, **2012**, 4, 234-50 | 12 | 70 |
| 33 | Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. *Nature*, **2011**, 479, 122-6 | 50.4 | 237 |
| 32 | Semaphorin signals on the road of endothelial tip cells. *Developmental Cell*, **2011**, 21, 189-90 | 10.2 | 20 |
| 31 | Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. *Molecular Aspects of Medicine*, **2011**, 32, 71-87 | 16.7 | 79 |
| 30 | HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. *Cancer Cell*, **2011**, 19, 31-44 | 24.3 | 528 |
| 29 | Systemic and targeted delivery of semaphorin 3A inhibits tumor angiogenesis and progression in mouse tumor models. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 741-9 | 9.4 | 93 |
| 28 | Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. *Nature Reviews Clinical Oncology*, **2011**, 8, 393-404 | 19.4 | 215 |
| 27 | Role of delta-like-4/Notch in the formation and wiring of the lymphatic network in zebrafish. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2010**, 30, 1695-702 | 9.4 | 98 |
| 26 | Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery. *Circulation*, **2010**, 122, 273-81 | 16.7 | 30 |
| 25 | Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. *Cancer Research*, **2010**, 70, 6537-47 | 10.1 | 43 |
| 24 | Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. *Gastroenterology*, **2010**, 138, 1143-54.e1-2 | 13.3 | 98 |
| 23 | Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. *Cell*, **2010**, 141, 178-90 | 56.2 | 218 |
| 22 | Sema3E-Plexin D1 signaling drives human cancer cell invasiveness and metastatic spreading in mice. *Journal of Clinical Investigation*, **2010**, 120, 2684-98 | 15.9 | 123 |
| 21 | Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. *Cancer Cell*, **2009**, 15, 167-70 | 24.3 | 329 |
| 20 | Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. *Nature Reviews Clinical Oncology*, **2009**, 6, 315-26 | 19.4 | 159 |
| 19 | Role and therapeutic potential of VEGF in the nervous system. *Physiological Reviews*, **2009**, 89, 607-48 | 47.9 | 319 |

| | | | |
|---|---|---|---|
| 18 | Regulation of angiogenesis by oxygen and metabolism. *Developmental Cell*, **2009**, 16, 167-79 | 10.2 | 293 |
| 17 | Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. *Cell*, **2009**, 136, 839-851 | 56.2 | 642 |
| 16 | Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. *Nature Genetics*, **2008**, 40, 170-80 | 36.3 | 383 |
| 15 | FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. *Nature Reviews Cancer*, **2008**, 8, 942-56 | 31.3 | 445 |
| 14 | "Active" cancer immunotherapy by anti-Met antibody gene transfer. *Cancer Research*, **2008**, 68, 9176-83 | 10.1 | 32 |
| 13 | The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. *Journal of Experimental Medicine*, **2008**, 205, 1155-71 | 16.6 | 79 |
| 12 | Metron factor-1 prevents liver injury without promoting tumor growth and metastasis. *Hepatology*, **2008**, 47, 2010-25 | 11.2 | 14 |
| 11 | Genetic targeting of the kinase activity of the Met receptor in cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 11412-7 | 11.5 | 35 |
| 10 | The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo. *Clinical Cancer Research*, **2007**, 13, 2191-8 | 12.9 | 25 |
| 9 | Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. *Cell*, **2007**, 131, 463-75 | 56.2 | 666 |
| 8 | Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 5090-5 | 11.5 | 137 |
| 7 | The Met pathway: master switch and drug target in cancer progression. *FASEB Journal*, **2006**, 20, 1611-21 | 6.9 | 110 |
| 6 | Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. *Cancer Cell*, **2004**, 6, 61-73 | 24.3 | 261 |
| 5 | An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. *Journal of Clinical Investigation*, **2004**, 114, 1418-32 | 15.9 | 79 |
| 4 | Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. *Cancer Cell*, **2003**, 3, 347-61 | 24.3 | 1111 |
| 3 | An HGF-MSP chimera disassociates the trophic properties of scatter factors from their pro-invasive activity. *Nature Biotechnology*, **2002**, 20, 488-95 | 44.5 | 22 |
| 2 | DNA Methylation Repels Binding of HIF Transcription Factors to Maintain Tumour Immunotolerance | | 2 |
| 1 | PYCR1-dependent proline synthesis in cancer-associated fibroblasts is required for the deposition of pro-tumorigenic extracellular matrix | | 3 |